Aptose Biosciences
APTO
APTO was delisted on the 1st of April, 2025.
3 hedge funds and large institutions have $28.1K invested in Aptose Biosciences in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0.94% less ownership
Funds ownership: 0.94% → 0% (-0.94%)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $19
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$19 |
APTO Hedge Fund Activity: Q3 2025 in Review
3 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q3 2025, worth a combined $28.1K — up 35% from $20.7K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of APTO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was TD Waterhouse Canada, exiting entirely with an estimated $19 sold.
- 3 institutional investors held Aptose Biosciences (APTO) as of Q3 2025, down from 4 in Q2 2025.
- Funds reported $28.1K of Aptose Biosciences stock for Q3 2025, up 35% quarter-over-quarter.
- 0 funds opened new Aptose Biosciences positions in Q3 2025 and 1 closed out, a net change of -1 holder.
- The largest Aptose Biosciences seller in Q3 2025 was TD Waterhouse Canada, an estimated $19 sold.
Based on aggregated 13F filings for Q3 2025.